WARF Therapeutics collaborates with researchers to advance their work closer to clinical testing, a “bench to bedside” approach. The program invests in the development of drug-like molecules using industry-centric drug discovery resources and approaches led by a team of preclinical drug discovery experts.
We encourage researchers to meet with Jon Young to discuss their program and learn more about WARF Therapeutics. Principal investigators are invited to submit stage 0 and stage 1 project proposals by April 15, 2022, which will be reviewed at our spring Scientific Advisory Board meeting on May 16. Please review our new funding mechanisms that were recently initiated.
- UW-Madison or Morgridge Institute for Research principal investigators
- Novel disease targets that require target validation
- Translational research with a validated target and therapeutic disease hypothesis
- Patent not required